Movement Disorders

Henry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to discuss the resources and tools used to adapt to the COVID-19 pandemic.

The Merz Therapeutics product, marketed as Xeomin, is the first and only FDA-approved neuromodulator available for patients aged 2 years and older with chronic sialorrhea.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to discuss whether the COVID-19 pandemic forced clinicians to change treatment regimens or prescriptions.

PTC Therapeutics announced the initiation of its third study of 2020 investigating vatiquinone.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to assess how the COVID-19 virus affected the pathology of neurologic disorders.

There were no observations of clinical resistance or secondary treatment failure due to neutralizing antibodies, supporting the importance of the treatment’s unique purification process through XTRACT technology.

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss how they adopted new methods of care throughout the COVID-19 pandemic.

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss how the COVID-19 pandemic has affected telemedicine.

This specialty series is dedicated to assessing the impact COVID-19 has had on the quality of life of patients with neurological disorders and the clinicians who were forced to adapt during this unique era of medical history.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 18, 2020.

The executive director of the Norman Fixel Institute for Neurological Diseases provided his thoughts on changing the perception of humanitarian device exemptions.

Here's what is coming soon to NeurologyLive.

MDS-UPDRS score improvements from baseline were significantly greater in patients using the Personal KinetiGraph.

Pimavanserin (Nuplazid; Acadia) is indicated for hallucinations and delusions associated with Parkinson disease psychosis, and the capsules can now be emptied onto food for patients with swallowing issues.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 11, 2020.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases detailed the collaborative effort needed to see sustainable change in the approval system of neurological devices.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 4, 2020.

Study author Luc Evers and coauthor Bastiaan R. Bloem, MD, PhD, FRCPE, offer insight into the findings of a recent study assessing early treatment in PD.

In non-demented patients with Parkinson disease, hippocampal subfields showed associations with memory, spatial working memory, language and executive functions, and CSF tau levels.

The executive director of the Norman Fixel Institute for Neurological Diseases discussed the role insurance companies play within the system for approving neurological devices for rare diseases.

Here's what is coming soon to NeurologyLive.

The executive director of the Norman Fixel Institute for Neurological Diseases discussed the issues within the current system that prevent approvals for neurologic devices for rare diseases.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 27, 2020.

The chief scientific officer of the Parkinson’s Foundation offers his side of the debate on whether genetic testing for patients with Parkinson disease is under-utilized.

Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases sat down to discuss his viewpoint paper on changing the approval system for neurotechnological devices in rare diseases.

Researchers from the Mayo Clinic found a molecular target that can help assess potential treatments for spinocerebellar ataxia type 3, a disease which currently has no cure.

Here's what is coming soon to NeurologyLive.